Boys but Not Girls with T-Lineage Acute Lymphocytic Leukemia (ALL) Are Different from Children with B-Progenitor ALL

Imbach, Paul; Fuchs, Andreas; Berchtold, Willi; Arnet, B.; A, Stupnicki; Angst, R.; Signer, E

doi:10.1097/00043426-199511000-00012

Cited by 9 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have considered and reported the effect of race [28][29][30], number of primaries [27,31], and radiation therapies [32], chemotherapy [33][34][35], sex [27,32,[36][37][38][39]. Most of these factors were assessed by this present study and were found to be associated with survival.…”

Section: Discussionmentioning

confidence: 68%

Age Variance in the Survival of United States Pediatric Leukemia Patients (1973–2006)

et al. 2012

View full text Add to dashboard Cite

Background. Age at diagnosis remains an important prognostic factor in pediatric leukemia. However, it is not fully understood which prognostic factors are related to its effect on survival. This study aimed to assess the effect of age at diagnosis on pediatric leukemia survival in the United States (US). Methods. We utilized the Surveillance Epidemiology and End Results (SEER) data of the diagnosed pediatric leukemia patients (n = 15215) from . Life table, Kaplan-Meier, log rank test, and Cox proportional hazard methods were used to examine the data. Results. The overall 5-year survival was 67.9%. Infants and children of 18 and 19 years had the highest risk of dying, with a rapid declining risk of death at age of 1 year that continued until age of 3 years and thereafter a steady trend of increased risk of death. The increased risk of dying was associated with boys, T-cell type and more than one primary tumor, P < 0.0001. There was significant variability in survival by the age group at diagnosis. Compared to age group <1 year, children of ages 1-4 years, 5-9 years, 10-14 years, and 15-19 years were 76% (adjusted hazard ratio (AHR) = 0.24, 99% CI = 0.21-0.28), 69% (AHR = 0.31, 99% CI = 0.26-0.36), 46% (AHR = 0.54, 99% CI = 0.46-0.62), and 18% (AHR = 0.82, 99% CI = 0.70-0.95) less likely to die, respectively. Conclusion. The age at tumor diagnosis was a single most potent prognostic factor of childhood leukemia survival, with infants and children of age group 15-19 years experiencing the poorest survival. This significant variability persisted after adjustment for the effect of other covariates. Therefore, there is a need to identify other prognostic factors that are associated with age in order to provide a meaningful explanation of the impact of age on pediatric leukemia survival in the US.

show abstract

Section: Discussionmentioning

confidence: 68%

Age Variance in the Survival of United States Pediatric Leukemia Patients (1973–2006)

et al. 2012

View full text Add to dashboard Cite

show abstract

Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience

Robak

Szmigielska-Kapłon

Wrzesień‐Kuś

et al. 2004

Annals of Hematology

View full text Add to dashboard Cite

This is a retrospective, multicenter study to evaluate biological features and outcome of elderly patients diagnosed with acute lymphoblastic leukemia (ALL) during the last 10 years in ten hematological centers in Poland. Eighty-seven patients aged 60 years or older were studied. To our knowledge, this is one of the largest group of elderly patients with ALL evaluated. We have not observed differences in immunological subtypes and Ph chromosome incidence as compared with younger adult ALL presented in the literature. Induction chemotherapy was administered in 75 patients. We observed complete remission (CR) in 34 (45%, 95% CI: 33-56%) patients. Induction death occurred in 11 (15%) patients. Thirty patients (40%) showed primary resistance to chemotherapy. Median overall survival (OS) of all patients was 150 days. Median disease-free survival (DFS) of responding patients was 180 days. We observed four long-term survivors (DFS longer than 3 years) in our group of patients. Factors influencing OS were CR achievement, female gender, and WBC below 30 x 10(9)/l. Male gender was the only prognostic factor negatively affecting probability to achieve CR. We have not observed any differences in either biology or outcome between patients aged 60-69 years and those aged more than 70 years. ALL of the elderly is a rare disease with poor prognosis. Further clinical trials evaluating the disease features, outcome, and new therapeutic approaches are warranted.

show abstract

Gender-Specific Aspects of Pediatric Hematology and Oncology

Garvin¹

2010

Principles of Gender-Specific Medicine

View full text Add to dashboard Cite

Boys but Not Girls with T-Lineage Acute Lymphocytic Leukemia (ALL) Are Different from Children with B-Progenitor ALL

Cited by 9 publications

References 0 publications

Age Variance in the Survival of United States Pediatric Leukemia Patients (1973–2006)

Age Variance in the Survival of United States Pediatric Leukemia Patients (1973–2006)

Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience

Gender-Specific Aspects of Pediatric Hematology and Oncology

Contact Info

Product

Resources

About